M
Moraima Zelada-Hedman
Researcher at Karolinska Institutet
Publications - 6
Citations - 2987
Moraima Zelada-Hedman is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 5, co-authored 6 publications receiving 2915 citations.
Papers
More filters
Journal ArticleDOI
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
D Ford,Douglas F. Easton,Michael R. Stratton,Steven A. Narod,David E. Goldgar,Peter Devilee,D. T. Bishop,Barbara L. Weber,Gilbert M. Lenoir,Jenny Chang-Claude,Hagay Sobol,M D Teare,Jeffery P. Struewing,Adalgeir Arason,Siegfried Scherneck,Julian Peto,Timothy R. Rebbeck,Patricia N. Tonin,Susan L. Neuhausen,Rosa B. Barkardottir,Jorunn E. Eyfjord,Henry T. Lynch,Bruce A.J. Ponder,Simon A. Gayther,J.M. Birch,Annika Lindblom,Dominique Stoppa-Lyonnet,Y. J. Bignon,Åke Borg,U Hamann,Neva E. Haites,Rodney J. Scott,Christine Maugard,Hans F. A. Vasen,Susanne Seitz,Lisa A. Cannon-Albright,Andrew Craig Schofield,Moraima Zelada-Hedman +37 more
TL;DR: The lifetime risk of breast cancer appears similar to the risk in BRCA1 carriers, but there was some suggestion of a lower risk in bRCA2 carriers <50 years of age.
Journal Article
A Screening for BRCA1 Mutations in Breast and Breast-Ovarian Cancer Families from the Stockholm Region
Moraima Zelada-Hedman,Brita Arver,Antonio Claro,Jindong Chen,Barbro Werelius,Helen Kok,Kerstin Sandelin,Sara Håkansson,Tone Ikdahl Andersen,Åke Borg,Anne Lise Børresen Dale,Annika Lindblom +11 more
TL;DR: To identify BRCA1 germ-line mutations in the breast and breast-ovarian cancer families in the Stockholm region, DNA from 174 patients from these families were studied using various mutation screening techniques, followed by direct DNA sequencing.
Journal ArticleDOI
Screening for TP53 mutations in patients and tumours from 109 swedish breast cancer families
Moraima Zelada-Hedman,Anne Lise Børresen-Dale,Antonio Claro,Jindong Chen,Lambert Skoog,Annika Lindblom +5 more
TL;DR: To estimate the prevalence of TP53 mutations in familial breast cancer, constant denaturant gel electrophoresis (CDGE) was used to screen exons 5-8 of the TP53 gene for germline mutations.
Journal ArticleDOI
TGFBR1 variants TGFBR1(*)6A and Int7G24A are not associated with an increased familial colorectal cancer risk.
J Skoglund Lundin,J Vandrovcova,Bo Song,Bo Song,Xiaoying Zhou,Moraima Zelada-Hedman,Barbro Werelius,Richard S. Houlston,Annika Lindblom +8 more
TL;DR: This study provides no substantial support for the hypothesis that the polymorphic variants TGFBR1*6A or Int7G24A contribute to familial CRC risk and cannot, however, exclude the possibility that TGF BR1 variants have a modifying effect on inherited risk per se.